drugset / Trial / NCT03766750

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

NCT03766750

Phase 3 Withdrawn EMS
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Lima association in the control of type 2 diabetes mellitus

Timeline

Start
2021-12
Primary completion
2023-10
Completion
2023-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Forxiga Unknown 10 mg Oral
Subject LIMA association Unknown Oral
Comparator Linagliptin Small molecule 5 mg Oral